Human immunodeficiency virus type 1 (HIV-1) is the widely accepted etiologic agent for AIDS. Gradual depletion of immune regulatory T cells and apoptosis (programmed cell death) may occur by direct effects of cytopathic HIV variants that may contribute to the attenuation and collapse of the immune system. The mechanism of cell depletion may include gpl20 binding to CD4 (29) and the upregulated release of cytokines such as tumor necrosis factor alpha or transforming growth factor beta (39) . Virus expression can be enhanced by activation with cofactors such as CD3 antibodies (29) or by activation of HIV long terminal repeat (LTR)-directed viral gene expression by exogenous viral infection, such as by herpes simplex virus (13, 30, 31, 34) , human cytomegalovirus (3, 5, 8) , human hepatitis B virus (41) , and human herpesvirus 6 (HHV-6) (9). Among them, HHV-6 may play a prominant role because HHV-6 and HIV-1 are similar in CD4+ cell tropism.
HHV-6 was first isolated from the peripheral blood mononuclear cells of six adult patients from the United States and Jamaica who had lymphoproliferative diseases and AIDS (40, 43) . The virus has also been isolated from infants with exanthem subitum (1, 42) and from patients with various other diseases. The virus is identified as the etiologic agent of exanthem subitum (42) . infects many of the same cell types as HIV-1 does (26) , and coinfection of T lymphocytes with HIV-1 and HHV-6 leads to accelerated cytopathic effects (26) . Infection of CD8+ cells by HHV-6 induces surface expression of CD4, rendering them susceptible to infection with HIV-1 (27) . The HIV-1 LTR is activated in HHV-6-infected primary human T lymphocytes (9) and T-cell lines (18) and leads to increased HIV-1 gene expression and virus replication. This activation is via nuclear factors binding to the HIV-1 LTR enhancer (9) . These observations suggest that HHV-6 may be an important cofactor in HIV-1 infection and may contribute to the progression of AIDS. However, other reports show that HHV-6 can suppress HIV-1 infection in vitro (6, 23) .
Previous studies conducted by Razzaque et al. (37, 38) have demonstrated that a genomic fragment, ZVH14, of strain GS can neoplastically transform NIH 3T3 and human keratinocyte cells. Horvat et al. (19) further purified on an 8% denaturing polyacrylamide gel, electroeluted into dialysis tubes, desalted by using NAP-25 chromatography (Pharmacia LKB), ethanol precipitated, and resuspended in distilled sterile water.
Transfection. Transfections of CV1 cells were performed by the calcium phosphate-DNA coprecipitation technique (15) . Precipitates were added to cells that had been plated 48 h before at a density of 3 x 105 to 5 x 105 cells per 100-mmdiameter dish. For most transfections, 1 pg of CAT plasmid was coprecipitated with effector plasmids and calf thymus DNA (to adjust the total DNA to 30 ,ug). Precipitates were left on the cells overnight (16 h), and then the monolayers were subjected to a 2-min 15% glycerol-DMEM shock. After being washed in phosphate-buffered saline, the cells were fed with 10 ml of DMEM containing 10% fetal bovine serum. Cells were harvested 48 h later for CAT enzyme activity analysis (2) . Each transfection was performed a minimum of two times in duplicate, with the contents of the two plates pooled at the time of cell harvest. Transfections of H9 cells were carried out by the DEAE-dextran method (25) .
CAT assay. CAT assays were carried out as described by Gorman et al. (14) , and the percentage of acetylation and fold induction were determined as described previously (2 driven by the simian virus 40 early promoter, and ligated by T4 DNA ligase. Clones were screened by the colony hybridization method described by Hanahan and Meselson (17) and confirmed by restriction analysis and sequencing.
DNA sequencing and sequence analysis. DNA sequencing was conducted by using a Sequenase version 2.0 kit (United States Biochemical) as specified by the manufacturer. Sequences were analyzed by the method of Pearson and Lipman (35) on an NIH Convex system.
RESULTS
Transactivation of the HIV LTR by the HHV-6 genomic fragment in pZVH14 is not just T-cell specific. The HIV LTR can be transactivated by HHV-6 infection in human T-cell lines and in primary human T cells (18, 19) . The 8.7-kb ZVH14 genomic segment of HHV-6 (GS) able to transactivate the HIV LTR when cotransfected into human T cells (19) . To determine whether HIV-1 LTR transactivation by pZVH14 is cell type specific, CV1 cells were used in transfection. CV1 cells have been used to study transactivation of the HIV LTR with various cofactors. Cotransfection of the HIV LTR CAT construct with pZVH14 resulted in a more than 10-fold increase in CAT enzymatic activity (Fig. 1) . Consistent with previous report by Horvat et al. (19) , the pZVB70 fragment had stronger activity than pZVH14 (data not shown). Our data show that HHV-6 (GS) genomic fragment ZVH14 can also transactivate the HIV LTR in CV1 cells.
Role of NF-KB and Spl binding sites in pZVH14-induced transactivation of the HIV LTR. It has been reported that HHV-6 increases HIV-1 expression in coinfected T cells via nuclear factors binding to the HIV-1 enhancer (9) and that NF-KB sites are required for another HHV-6 22-kb genomic subclone, pZVB70, to transactivate the HIV LTR (11, 19) . To map the elements required for transactivation by pZVH14, a series of HIV LTR deletion constructs containing from one to three Spl sites but without NF-KB sites was tested for response to pZVH14. Deletion of NF-KB enhancer elements did not cause a large reduction of basal-level promoter activity (Fig. 1) Using constructs varying in number of Spl sites, we found that pZVH14 activated transcription at a moderate level (threefold) from -57CAT containing Spl site I, as determined by liquid scintillation counting (Fig. 1) . This activation was more than eightfold with -69CAT, which contains two Spl sites (I and II). The presence of the third Spl site (site III) in -83CAT further enhanced the basal-level transcription, and transactivation was elevated up to 11-fold. No elevated CAT activity was observed in the -29CAT construct, which contains the TATA and TAR elements with all three Spl binding sites being deleted. The data presented here indicate that for efficient transactivation, more than one Spl site is required, which is consistent with the reports of Jones et al. (20) .
To confirm this finding, constructs containing the two NF-KB sites and the TATA and TAR sites with variable numbers of Spl sites were used (Fig. 2) . Internal deletion of all three Spl sites with the presence of NF-KB, TATA, and TAR sites (-117SP3/1) caused the complete loss of transactivation by pZVH14, while this construct can still be transactivated by tax and tat (46) . This finding indicates that even at low basal activity of an Spl-less construct, transactivation is possible, and pZVH14 failed to transactivate it because of the absence of Spl sites. With the presence of NF-KB, Spl site I, TATA, and TAR (-117SP3/2), subtle levels of transactivation were observed. With the presence of NF-KB, Spl sites I and II, TATA, and TAR (-117SP3), enhanced activation was observed. These studies indicated that Spl binding sites are essential and that maximal stimulation of the HIV LTR by pZVH14 requires Spl sites I and II.
Inhibition of pZVH14-elevated transcription of the HIV-1 LTR by oligomers designed to form a triplex with Spl binding sites. Several studies have demonstrated that oligomers can inhibit promoter activities through formation of triplex with certain elements of promoters. The formation of a triplex DNA molecule (forming a T:AT triplet or C+:GC triplet) occurs through the binding of polypurine oligonucleotides to a polypurine/polypyrimidine site in a sequence-specific manner (32) . It has also been demonstrated that the presence of strictly polypurine/polypyrimidine DNA sequences is not absolutely necessary for the formation of triplex DNA (4, 45) . A non strictly polypyrimidine:polypurine/polypyrimidine site can form a triplex which can also functionally inhibit transcription in vitro and in vivo (4, 7, 10, 33, 44, 45) . Although the sequence of the Spl binding site of the HIV LTR is not purely polypurine/polypyrimidine, it has been demonstrated that it may form triplex DNA under certain conditions and suppress viral replication by inhibiting transcription and transactivation (28) . In this experiment, three oligomers, HIVSp, HIVSpC, and HIV NF-KB, were designed. HIVSp is the parallel form of HIV LTR -46 to -79 with substitutions of A to T and C to G. HIV NF-KB is the parallel form of HIV LTR -82 to -103 with substitutions of A to T and C to G. HIVSpC has the same base composition as HIVSp but contains designated point mutations with respect to HIVSp. To test whether these oligomers can inhibit pZVH14-induced transactivation of the HIV LTR, they were cotransfected with HIV LTR CAT and pZVH14 into CV1 cells, and CAT activity was measured. As illustrated in Fig. 3, Hind 111
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site, and protein sequence is shown (Fig. 6) (Fig. 7B) . This finding demonstrated that r identify and characterize the pSV-B115 is capable of transactivating the HIV-1 LTR in an ansactivation of the HIV-1 LTR, Spl-dependent manner in CV1 and human T cells. several deletions and truncation clones of the 8.7-kb ZVH14 insert were constructed and tested for the ability to transactivate the HIV LTR. The transactivation level of each clone is shown in Fig. 4 . All clones (pZVH14-1, pZVH14-2, pZVH14-3, pZVH14-4, pZVH14-8, and pZVH14-9) which contain the 1-kb HincII-XbaI fragment were capable of transactivating the HIV LTR. Clones which contained the righthand 0.8-kb PstI-HindIII fragment were also able to consistently transactivate the HIV LTR (fourfold). These studies B. cotransfection experiments of various HIV-1 LTR CAT constructs with HHV-6 (GS) gene segment pZVH14, we have examined the function of individual known regulatory elements of the HIV-1 LTR in pZVH14-induced transactivation. Our data indicated that pZVH14 transactivated the HIV-1 LTR through the Spi binding sites and that NF-KB sites are not essential in transactivation. Another study has demonstrated that NF-KB binding sites are necessary for transactivation of the HIV-1 LTR by another HHV-6 (GS) gene segment, pZBV70 (11) . Together, the data suggest that activation of the HIV-1 LTR by HHV-6 involves at least two HHV-6 genes and multiple response elements within the HIV promoter. A similar phenomenon has been observed whereby both Spl and NF-KB sites in the HIV LTR are required for transactivation by HSV-l infection (30) .
From this study, it is clear that efficient transactivation of the HIV LTR by pZVH14 requires functional Spl binding sites. Since an HIV LTR construct containing Spl binding sites I and II (-1 17SP3) was efficiently transactivated by pZVH 14. In contrast, the HIV LTR construct containing only Spl binding site I showed poor activation, suggesting that pZVH14 requires at least two tandem Spl binding sites to exert its optimal function. Also, the triplex formation data in Fig. 3 suggest that activation is Spl site specific, since NF-KB did not show significant blocking function. The same triplex oligomer, HIVSp, could also specifically block transcription of the HIV LTR but did not form a triplex with regulatory regions of c-myc and interleukin 2 receptor promoters as shown by McShan et al. (28) . The major trans-acting domain of pZVH14 is localized to a small fragment which contains a 115-amino-acid ORF (B115). It is likely that this 115-amino-acid ORF is responsible for Spl-dependent transactivation.
There are several possible mechanisms by which Spl-dependent transactivation may occur. First, the putative protein may directly bind to Spl sites in a similar fashion as the cellular transcription factor Spl. Second, it may act as a coactivator by or pSV-B115 used in directly or indirectly interacting with SpI or its family members (12, 24, 36) , such as bovine papillomavirus E2 (24) . Third, it may interfere with the posttranslational modification of Spl, such as phosphorylation. Finally, it may activate expression of cellular genes which may be involved in transactivation, such as tumor necrosis factor-induced Spl in micromuscular cells (16) , although expression of Spl family members, unlike that of NF-KB or AP-1 family members, is relatively stable and usually constitutive.
Sequence analyses indicate that there are one GATA box 30 bp and one TATA box 98 bp upstream of the first ATG codon and a polyadenylation signal sequence (ATTAAA) at position 154 bp downstream of the putative ORF B115 (Fig. 6) (22) , studies to localize the transforming activity in this segment are also in progress.
